Vera Therapeutics, Inc.
VERA
Positions held
Your positionsVERA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Vera Therapeutics operates in the biotechnology sector, which is known for rapid innovation and potential breakthroughs in healthcare.
- The company's market cap stands at approximately $2.12 billion, indicating a significant valuation in the biotech space.
- Vera has a strong buy recommendation with a target mean price of $77.5, suggesting potential upside.
- Vera Therapeutics has reported zero revenue for multiple quarters, raising concerns about its business viability.
- The company has incurred substantial net losses, with a net income of -109.473 million in Q2 2026.
- Vera's financial health is concerning, as indicated by a strong sell score of -27.00, with multiple bearish signals in its trend analysis.
Fundamentals
| Market cap | $2.14B | Enterprise value | $1.72B | Trailing P/E | — | Forward P/E | -6.98 |
| PEG | — | Price / book | 5.25 | Beta | 1.05 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -91.8% | ROA | -46.8% | Debt / equity | 0.19 |
| Current ratio | 10.92 | Free cash flow | -$212.95M | Analyst recommendation | strong_buy | Mean target | $77.50 |
| 52w high | $56.05 | 52w low | $23.05 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$109M | -$121M | -$91.1M | -$80.3M | -$76.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$112M | -$125M | -$94.2M | -$83.9M | -$80.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$300M | -$152M | -$96.0M | -$89.1M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$315M | -$167M | -$102M | -$90.9M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Do Vera Therapeutics' (VERA) High-Profile IgAN Data Show Durable Moat or Crowded Mechanism Risk?
2026-10-02 · Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-24 · Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
2026-09-17 · 2 ‘Strong Buy’ Stocks Where a Short Squeeze Could Be Brewing
2026-09-17 · Vera Therapeutics (VERA) Says TRUTAKNA Met All Phase III Endpoints
2026-09-16 · Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
2026-09-15 · Vera Reverses Its Major Chart Upset As Vertex Rivalry Deepens — What Happened?
2026-09-15 · Vera set up for full approval for Trutakna in IgAN with Phase III win
2026-09-15 · Why Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial Results
2026-09-15 · Vera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial Endpoints
Price (daily)
Full chart · RSI · MACD · patterns